Avita Medical financials
$11.96+2.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.7M | $19.3M | $17.6M | $17.1M | $18.4M | $18.5M | $18.4M | $19.5M | $15.2M | $11.1M | $14.2M | $13.6M |
| Gross profit | $17.8M | $15.7M | $14.3M | $13.9M | $14.9M | $15.7M | $16.1M | $16.4M | $13.1M | $9.6M | $12.4M | $11.5M |
| Gross margin | 81.9% | 81.7% | 81.2% | 81.3% | 81.2% | 84.7% | 87.6% | 83.7% | 86.1% | 86.4% | 87.3% | 84.5% |
| Operating income | -$6.9M | -$8.8M | -$10.4M | -$9.2M | -$11.1M | -$11.8M | -$10.0M | -$13.8M | -$15.6M | -$17.2M | -$12.3M | -$9.3M |
| Net income | -$7.7M | -$10.6M | -$11.6M | -$13.2M | -$9.9M | -$13.9M | -$11.6M | -$16.2M | -$15.4M | -$18.7M | -$7.1M | -$8.7M |
| Net margin | −35.3% | −55.1% | −66.0% | −77.3% | −53.9% | −74.9% | −63.0% | −82.9% | −101.3% | −168.0% | −49.8% | −63.8% |
| Diluted EPS | $-0.25 | $-0.35 | $-0.38 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 |
| EBITDA | -$6.3M | -$8.2M | -$9.7M | -$8.6M | -$10.6M | -$11.3M | -$9.5M | -$13.5M | -$15.4M | -$17.0M | -$12.0M | -$9.1M |
| Operating cash flow | -$3.5M | -$10.1M | -$5.4M | -$5.2M | -$10.2M | -$10.3M | -$8.1M | -$7.2M | -$12.8M | -$20.9M | -$10.9M | -$9.0M |
| Free cash flow | -$3.6M | -$10.1M | -$6.1M | -$6.2M | -$10.8M | -$10.5M | -$9.7M | -$11.0M | -$15.4M | -$22.0M | -$11.2M | -$9.5M |
| Diluted shares | 30.7M | 30.5M | 30.4M | 28.4M | 26.4M | 26.3M | 26.2M | 26.0M | 25.8M | 25.6M | 25.5M | 25.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.1M | $8.3M | $10.2M | $15.4M | $12.2M | $14.9M |
| Short-term investments | $2.0M | $6.0M | $7.9M | $7.9M | $3.5M | $10.9M |
| Total debt | $46.7M | $46.1M | $43.0M | $42.4M | $42.2M | $41.5M |
| Total assets | $47.8M | $51.5M | $56.4M | $63.7M | $58.1M | $69.6M |
| Total liabilities | $75.6M | $74.7M | $73.0M | $70.4M | $71.0M | $74.1M |
| Shareholders' equity | -$27.8M | -$23.2M | -$16.6M | -$6.7M | -$12.8M | -$4.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology